Program
Vitamin B 12
Also written as “Vitamin B12, Vitamin B6, Folic acid”, “Nascobal nasal spray (cyanocobalamin, USP)” and “Cyanocobalamin”.
Its studies are mostly in Vitamin B 12 Deficiency, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Medice Arzneimittel Pütter GmbH & Co KG | 10 open or running | phase 4since May 1, 2025 | May 1, 2025 | none ahead |
| Novo Nordisk | 10 open or running | no phasesince Mar 8, 2011 | Mar 8, 2011 | none ahead |
| Swedish Orphan Biovitrum | 10 open or running | phase 1since Feb 28, 2011 | Feb 28, 2011 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 28, 2011First study: phase 1 study in Focus: BioavailabilityNew to Swedish Orphan BiovitrumSwedish Orphan Biovitrum · NCT01306123 · 16 enrolled · Sweden
- Mar 8, 2011Novo Nordisk's first study: no phase study in HealthyNew to Novo NordiskNovo Nordisk · NCT01311739 · 20 enrolled
- May 1, 2025Medice Arzneimittel Pütter GmbH & Co KG's first study: phase 4 study in Vitamin B 12 DeficiencyNew to Medice Arzneimittel Pütter GmbH & Co KGMedice Arzneimittel Pütter GmbH & Co KG · NCT07029698 · 46 enrolled · Ukraine
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07029698Vitamin B 12 Deficiency · Ukraine | 4 | Completed | Medice Arzneimittel Pütter GmbH & Co KG | Oct 7, 2025 | 46 |
| NCT01311739Healthy | – | Completed | Novo Nordisk | 20 | |
| NCT01306123Focus: Bioavailability · Sweden | 1 | Completed | Swedish Orphan Biovitrum | May 2011 | 16 |
How it is read
Names in the registry
- “Vitamin B12, Vitamin B6, Folic acid”, 1 entry
- “Nascobal nasal spray (cyanocobalamin, USP)”, 1 entry
- “Cyanocobalamin”, 1 entry
Conditions, from the studies’ own filings
- Vitamin B 12 Deficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.